148 related articles for article (PubMed ID: 34876833)
1. Development and Validation of a Prognostic N6-Methyladenosine-Related Immune Gene Signature for Lung Adenocarcinoma.
Zhang L; Luo Y; Cheng T; Chen J; Yang H; Wen X; Jiang Z; Li H; Pan C
Pharmgenomics Pers Med; 2021; 14():1549-1563. PubMed ID: 34876833
[TBL] [Abstract][Full Text] [Related]
2. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
3. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
4. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
[TBL] [Abstract][Full Text] [Related]
5. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
6. N6-methyladenosine methylation related immune biomarkers correlates with clinicopathological characteristics and prognosis in clear cell renal cell carcinoma.
Huang Z; Kang W; Zhang Q
Transl Cancer Res; 2022 Jun; 11(6):1576-1586. PubMed ID: 35836532
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma.
Wang X; Yu Q; Yu H; Wang Y; Sun L; Yu L; Cui H; Yang H
Am J Transl Res; 2022; 14(8):5379-5393. PubMed ID: 36105012
[TBL] [Abstract][Full Text] [Related]
8. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Genomic Instability of m
Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906
[No Abstract] [Full Text] [Related]
10. Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma.
Weng C; Wang L; Liu G; Guan M; Lu L
Front Oncol; 2021; 11():763027. PubMed ID: 34868980
[TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes.
Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
Cancer Cell Int; 2021 Apr; 21(1):219. PubMed ID: 33858449
[TBL] [Abstract][Full Text] [Related]
12. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
Front Genet; 2022; 13():862741. PubMed ID: 35368663
[No Abstract] [Full Text] [Related]
13. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Chen J; Zhou R
PeerJ; 2021; 9():e10628. PubMed ID: 33520448
[TBL] [Abstract][Full Text] [Related]
14. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
15. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
[TBL] [Abstract][Full Text] [Related]
16. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
17. A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma.
Yang X; Wang G; Gu R; Xu X; Zhu G
PeerJ; 2020; 8():e10418. PubMed ID: 33304656
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
19. N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma.
Sun J; Ping Y; Huang J; Zeng B; Ji P; Li D
Front Cell Dev Biol; 2021; 9():705962. PubMed ID: 34422827
[TBL] [Abstract][Full Text] [Related]
20. Effect of N6-methyladenosine (m6A) regulator-related immunogenes on the prognosis and immune microenvironment of breast cancer.
Yu Z; He Q; Xu G
Transl Cancer Res; 2022 Dec; 11(12):4303-4314. PubMed ID: 36644186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
